A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

NCT06312020 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

209

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated by sponsor due to meeting pre-defined criteria for futility.

Conditions

Sjogren's Syndrome

Interventions

DRUG: HZN-1116
DRUG: Placebo

Sponsor

Amgen